Similar articles

• Clinical outcome of anti-HCV(+) renal allograft recipients.

  Lee SW, Kang SW, Choi KH, Han KH, Lee HY, Han DS, Kim YS, Park K. Lee SW, et al. Transplant Proc. 1996 Jun;28(3):1501-2. Transplant Proc. 1996. PMID: 8658759 No abstract available.
• Risk of chronic liver disease in HBsAG and/or anti-HCV-positive renal allograft recipients.

  Durlik M, Gaciong Z, Soluch L, Walecka-Zielecka B, Rancewicz Z, Rowińska D, Rowiński W, Szmidt J, Lao M. Durlik M, et al. Transplant Proc. 1996 Feb;28(1):50-1. Transplant Proc. 1996. PMID: 8644327 No abstract available.
• Impact of donor hepatitis B antigenemia on renal allograft in hepatitis B recipients.

  Chen JB, Hsieh H, Hsu KT, Chen CH. Chen JB, et al. Transplant Proc. 1996 Jun;28(3):1490-2. Transplant Proc. 1996. PMID: 8658755 No abstract available.
• Renal transplantation in patients positive for hepatitis B or C (pro).

  Morales JM. Morales JM. Transplant Proc. 1998 Aug;30(5):2064-9. doi: 10.1016/s0041-1345(98)00542-9. Transplant Proc. 1998. PMID: 9723394 Review. No abstract available.
• Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies.

  Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Fabrizi F, et al. Am J Transplant. 2005 Jun;5(6):1452-61. doi: 10.1111/j.1600-6143.2005.00864.x. Am J Transplant. 2005. PMID: 15888054